Antagonists, Cell Biology, Cell Signaling and Neuroscience, Dopaminergics, Lipids in Cell Signaling, Neuroscience, Neurotransmission, Neurotransmitters, Phospholipase Inhibitors, Phospholipid Metabolism
{SNA} Antagonists, Cell Biology, Cell Signaling and Neuroscience, Dopaminergics, Lipids in Cell Signaling, Neuroscience, Neurotransmission, Neurotransmitters, Phospholipase Inhibitors, Phospholipid Metabolism
{SNA} Antagonists, Bioactive Small Molecule Alphabetical Index, Dopaminergics, H, Lipids in Cell Signaling,
相关文献及参考
[2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7.
[3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839.
1. Loonen, A.J., et al., Halopemide and benzodiazepine binding sites Arch. Int. Pharmacodyn. Ther. 258 , 1982, (51)
Monovich, L., et al, Optimization of Halopemide for Phospholipase D2 inhibition. Bioorg. Med. Chem. Lett. 17 , 2310-2311, (2007) 摘要
Scott, SA., et al, Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nature Chem. Biol. 2 , 108-117, (2009) 摘要
Wenjuan, Su., et al, FIPI, a Phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol. Pharmacol. 2008 , 1, (2008) 摘要